BioSpace News Archive

Ocuphire Pharma, Inc. (Nasdaq: OCUP) today announced that a presentation titled, Safety and Efficacy of an Oral Therapeutic APX3330 from ZETA-1 Phase 2 Trial in Patients with Diabetic Retinopathy, was delivered by David Lally, M.D. F.A.S.R.S. at the Clinical Trials at the Summit (CTS) 2023 meeting in Park City, Utah on Saturday, June 10.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces that new data from studies with NUZYRA® (omadacycline) will be presented at ASM Microbe 2023 conference.

On June 12, China Medical System Holdings Limited (“CMS” or the “Group”) announced that on June 7 2023, the New Drug Application (NDA) of Diazepam Nasal Spray (the “Product”) received approval from the National Medical Products Administration of China (NMPA).

U.S. Health and Human Services Department Secretary Xavier Becerra will kick off the National Association for Behavioral Healthcare’s 2023 Annual Meeting at the Salamander Washington, D.C.

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development.

Creative Medical Technology Holdings, Inc., a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, provided an update on recent business activities.

RedHill Biopharma Ltd. (NASDAQ: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today reported its first quarter 2023 financial results and operational highlights.

Creative Medical Technology Holdings, Inc., a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, announced that its Board of Directors has approved a share repurchase program.

Stevanato Group S.p.A., a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, unveiled Vertiva™, the latest release of its patented On-Body Delivery System, intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies.

Charles River Laboratories International, Inc. (NYSE: CRL) and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, today announced a collaboration for adenoviral vector production.